PT  - JOURNAL ARTICLE
AU  - McGraw, Katlyn E.
AU  - Domingo-Relloso, Arce
AU  - Riggs, Daniel W.
AU  - Medgyesi, Danielle N.
AU  - Neupane, Raghavee
AU  - Stingone, Jeanette A.
AU  - Sanchez, Tiffany R.
TI  - Urinary Volatile Organic Compound Metabolites are Associated with High Blood Pressure Among Non-smoking Participants in the National Health and Nutrition Examination Survey (2011-2018)
AID  - 10.1101/2024.07.18.24310671
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.18.24310671
4099  - http://medrxiv.org/content/early/2024/07/19/2024.07.18.24310671.short
4100  - http://medrxiv.org/content/early/2024/07/19/2024.07.18.24310671.full
AB  - Background Volatile organic compounds (VOCs) are ubiquitous environmental pollutants. Exposure to VOCs is associated with cardiovascular disease (CVD) risk factors, including elevated blood pressure (BP) in susceptible populations. However, research in the general population, particularly among non-smoking adults, is limited. We hypothesized that higher VOC exposure is associated with higher BP and hypertension, among non-smokers.Methods We included four cycles of data (2011-2018) of non-smoking adults (n=4,430) from the National Health and Nutrition Examination Survey (NHANES). Urinary VOC metabolites were measured by ultra-performance liquid chromatography–mass spectrometry, adjusted for urine dilution, and log-transformed. We estimated mean differences in BP using linear models and prevalence ratio of stage 2 hypertension using modified Poisson models with robust standard errors. Models were adjusted for age, sex, race and ethnicity, education, body mass index, estimated glomerular filtration rate and NHANES cycle.Results Participants were 54% female, with a median age of 48 years, 32.3% had hypertension, and 7.9% had diabetes. The mean differences (95% CI) in systolic BP were 1.61 (0.07, 3.15) and 2.46 (1.01, 3.92) mmHg when comparing the highest to lowest quartile of urinary acrolein (CEMA) and 1,3-butadiene (DHBMA) metabolites. The prevalence ratios (PR) for hypertension were 1.06 (1.02, 1.09) and 1.05 (1.01, 1.09) when comparing the highest to lowest quartiles of urinary acrolein (CEMA) and 1,3-butadiene (DHBMA), respectively.Conclusions Exposure to VOCs may be relevant yet understudied environmental contributors to CVD risk in the non-smoking, US population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork in the authors' laboratories is supported by NIEHS grants P42ES023716, P42ES033719, P30ES009089, R01ES029967, and T32ES00732221.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants gave informed consent of the survey process and their rights as a participant, and the survey was approved by the National Center for Health Statistics Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data is available for download from the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC) website. https://wwwn.cdc.gov/nchs/nhanes/ 3HPMAN-Acetyl-S-(3-hydroxypropyl)-L-cysteineBMIBody mass indexBKMRBayesian Kernel Machine RegressionBPBlood pressureCEMAN-Acetyl-S-(2-carboxyethyl)-L-cysteineCIConfidence intervalsCVDCardiovascular diseaseDBPDiastolic blood pressureDHBMAN-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteineeGFREstimated glomerular filtrationHDLHigh density lipoprotein cholesterolHPMMAN-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteineMAMandelic acidMHBMA3N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteineMUt,t-Muconic AcidNHANESNational Health and Nutrition Examination SurveyPGAPhenylglyoxylic acidPIPsPosterior inclusion probabilities PMA – N-Acetyl-S-(phenyl)-L-cysteineSBPSystolic blood pressureVOCsVolatile organic compounds